Multiple Sclerosis Market
Multiple Sclerosis Market Size, Share & Trends Analysis Report By Types (PPMS, PRMS, RRMS, SPMS) By Diagnostics Technologies (MRI, Evoked Potential Test, Spinal Fluid Test, and Others) By Mode of Administration (Injectable Agents, Oral Agents, and Intravenous Therapy) By Drug Class (Immunomodulators, and Immunosuppressant) Forecast, 2026-2035
Industry Overview
Multiple sclerosis market was valued at $31.0 billion in 2025 and is projected to reach $57.3 billion by 2035, growing at a CAGR of 6.5% during the forecast period (2026-2035). The global multiple sclerosis market is expanding as healthcare systems adopt more advanced neurological care and clinicians increasingly emphasize early intervention strategies. Growing recognition of MS symptoms and broader use of specialized diagnostic tools are bringing more patients into treatment pathways sooner than before. Pharmaceutical companies are also investing heavily in developing therapies aimed at slowing long-term disability, which is strengthening the market’s therapeutic landscape. In addition, improvements in patient support programs and wider availability of treatment options are helping sustain long-term therapy adherence. Rising collaboration between research institutions and industry players is further accelerating the introduction of refined treatment approaches.
Market Dynamics
Innovation in High-Efficacy and Targeted Therapies
The global Multiple Sclerosis market is experiencing rapid advancement driven by high-efficacy therapies, including next-generation monoclonal antibodies and modern oral agents designed to provide stronger and earlier disease control. A growing focus on targeted mechanisms, such as S1P modulators and BTK inhibitors, is reshaping treatment standards and offering broader therapeutic options for patients. These innovations aim to slow disease progression more effectively while improving long-term outcomes. Overall, the market is transitioning toward precision-based, durable treatment solutions.
Rising Prevalence and Expanding Access in Emerging Regions
The prevalence of Multiple Sclerosis continues to rise globally due to improved diagnostic capabilities and greater disease awareness. This increasing patient pool is elevating the demand for disease-modifying therapies across all major regions. Emerging markets, particularly in Asia-Pacific and Latin America, are witnessing accelerated growth as healthcare infrastructure strengthens and access to advanced MS treatments expands. As investment in neurology care rises, these regions are becoming key contributors to future market expansion.
Market Segmentation
- Based on the type, the market is segmented into PPMS, PRMS, RRMS, and SPMS.
- Based on the diagnostic technologies, the market is segmented into MRI, evoked potential test, spinal fluid test, and others.
- Based on the mode of administration, the market is segmented into injectable agents, oral agents, and intravenous therapy.
- Based on the drug class, the market is segmented into immunomodulators and immunosuppressants.
MRI Segment to Lead the Market with the Largest Share
The use of MRI has become central to how clinicians identify and monitor Multiple Sclerosis, and this has contributed meaningfully to the market’s advancement. As imaging techniques have become more refined, physicians are able to confirm diagnoses with greater certainty, which brings patients into treatment at an earlier stage. Regular MRI follow-ups also help track subtle changes in disease activity, allowing timely adjustments to therapy. This clearer clinical oversight supports better patient management and increases demand for disease-modifying treatments. With the wider availability of high-resolution MRI systems across hospitals and specialty centers, the market is benefiting from more consistent diagnostic practices worldwide. Overall, enhanced imaging capability is playing a decisive role in shaping market growth.
Immunomodulators: A Key Segment in Market Growth
The expanding use of immunomodulators has grown into a key driver of progress in the Multiple Sclerosis market. These therapies help regulate abnormal immune responses, offering patients a more controlled approach to managing flare-ups and long-term disease progression. As newer formulations provide improved safety profiles and longer-lasting effectiveness, physicians are increasingly confident in prescribing them as part of early and ongoing care. Broader acceptance of these treatments has led to steady demand from both newly diagnosed patients and those transitioning from older therapies. Furthermore, ongoing research into next-generation immunomodulators is driving innovation across the market. These developments are strengthening the therapeutic foundation of MS care and contributing to sustained market expansion.
Regional Outlook
The global multiple sclerosis market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing Neurological Disorders in Europe
The European multiple sclerosis market is progressing as countries enhance their national guidelines for neurological disorders and expand dedicated MS care networks. Widespread access to specialized neurologists and structured rehabilitation services helps ensure timely treatment decisions. Many European health systems continue to update reimbursement frameworks, enabling broader use of modern therapies. Cross-border research collaborations are also contributing to the development of refined treatment approaches that reflect regional clinical priorities. Increased awareness campaigns and patient advocacy efforts are improving early recognition of symptoms across the continent. These combined developments are reinforcing the long-term growth outlook for the MS market in Europe.
North America Region Dominates the Market with Major Share
The multiple sclerosis market in North America is expanding as specialist clinics and hospitals continue to strengthen their neurological care capabilities. Patients in the region benefit from earlier assessments and structured follow-up routines, which have increased the uptake of advanced therapies. Insurance coverage for disease-modifying treatments has also become more comprehensive, encouraging consistent long-term care. In parallel, strong research activity across the U.S. and Canada is accelerating the introduction of improved therapeutic options. Growing participation in clinical trials is further broadening access to emerging treatments. Together, these elements are supporting steady and sustained market growth across North America.
Market Players Outlook
The major companies operating in the global multiple sclerosis market include Biogen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA (EMD Serono Inc.), Novartis AG, Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers and acquisitions strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In November 2025, Sandoz, the global leader in affordable medicines, announced that TYRUKO (natalizumab-sztn) is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).
- In November 2025, Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis. The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide.
- In September 2025, The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and brain-penetrant investigational Bruton's tyrosine kinase (BTK) inhibitor to treat non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. Sanofi is confident in the potential positive impact tolebrutinib can provide and will continue to collaborate closely with the FDA during the review period.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global multiple sclerosis market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Multiple Sclerosis Market Sales Analysis – Types | Diagnostics Technologies | Mode of Administration| Drug Class| ($ Million)
- Multiple Sclerosis Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Multiple Sclerosis Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Multiple Sclerosis Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Multiple Sclerosis Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Multiple Sclerosis Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Multiple Sclerosis Market Revenue and Share by Manufacturers
- Multiple Sclerosis Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Biogen Inc.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche Ltd.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Merck KGaA (EMD Serono Inc.)
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis (Subject to Data Availability)
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Biogen Inc.
- Key Company Analysis
- Global Multiple Sclerosis Market Sales Analysis by Types ($ Million)
- Primary Progressive MS
- Progressive Relapsing MS
- Relapsing Remitting MS
- Secondary Progressive MS
- Global Multiple Sclerosis Market Sales Analysis by Diagnostics Technologies ($ Million)
- MRI
- Evoked Potential Test
- Spinal Fluid Test
- Others
- Global Multiple Sclerosis Market Sales Analysis by Mode of Administration ($ Million)
- Injectable Agents
- Oral Agents
- Intravenous Therapy
- Global Multiple Sclerosis Market Sales Analysis by Drug Class ($ Million)
- Immunomodulators
- Immunosuppressant
- Regional Analysis
- North American Multiple Sclerosis Market Sales Analysis – Types | Diagnostics Technologies | Mode of Administration| Drug Class| Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Multiple Sclerosis Market Sales Analysis – Types | Diagnostics Technologies | Mode of Administration| Drug Class| Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Multiple Sclerosis Market Sales Analysis – Types | Diagnostics Technologies | Mode of Administration| Drug Class| Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Multiple Sclerosis Market Sales Analysis – Types | Diagnostics Technologies | Mode of Administration| Drug Class| Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Acorda Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Canon Medical Systems Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GE HealthCare Technologies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc (GSK)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson Services, Inc. (Janssen)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck KGaA (EMD Serono Inc.)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- TG Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Multiple Sclerosis Market Research And Analysis By Types, 2025-2035 ($ Million)
2. Global Primary Progressive MS Market Research And Analysis By Region, 2025-2035 ($ Million)
3. Global Progressive Relapsing MS Market Research And Analysis By Region, 2025-2035 ($ Million)
4. Global Relapsing Remitting MS Market Research And Analysis By Region, 2025-2035 ($ Million)
5. Global Secondary Progressive MS Market Research And Analysis By Region, 2025-2035 ($ Million)
6. Global Multiple Sclerosis Market Research And Analysis By Diagnostics Technologies, 2025-2035 ($ Million)
7. Global MRI For Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
8. Global Evoked Potential Test For Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
9. Global Spinal Fluid Test For Multiple Sclerosis Market Research And Analysis By Geography, 2025-2035 ($ Million)
10. Global Others Diagnostic Technologies For Multiple Sclerosis Market Research And Analysis By Geography, 2025-2035 ($ Million)
11. Global Multiple Sclerosis Market Research And Analysis By Mode Of Administration, 2025-2035 ($ Million)
12. Global Injectable Agents In Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
13. Global Oral Agents In Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
14. Global Intravenous Therapy In Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
15. Global Multiple Sclerosis Market Research And Analysis By Drug Class, 2025-2035 ($ Million)
16. Global Immunomodulators In Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
17. Global Immunosuppressant In Multiple Sclerosis Market Research And Analysis By Region, 2025-2035 ($ Million)
18. Global Multiple Sclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
19. North American Multiple Sclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
20. North American Multiple Sclerosis Market Research and Analysis by Types, 2025–2035 ($ Million)
21. North American Multiple Sclerosis Market Research and Analysis by Diagnostics Technologies, 2025–2035 ($ Million)
22. North American Multiple Sclerosis Market Research and Analysis by Mode of Administration, 2025–2035 ($ Million)
23. North American Multiple Sclerosis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
24. European Multiple Sclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
25. European Multiple Sclerosis Market Research and Analysis by Types, 2025–2035 ($ Million)
26. European Multiple Sclerosis Market Research and Analysis by Diagnostics Technologies, 2025–2035 ($ Million)
27. European Multiple Sclerosis Market Research and Analysis by Mode of Administration, 2025–2035 ($ Million)
28. European Multiple Sclerosis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
29. Asia-Pacific Multiple Sclerosis Market Research and Analysis by Country, 2025–2035 ($ Million)
30. Asia-Pacific Multiple Sclerosis Market Research and Analysis by Types, 2025–2035 ($ Million)
31. Asia-Pacific Multiple Sclerosis Market Research and Analysis by Diagnostics Technologies, 2025–2035 ($ Million)
32. Asia-Pacific Multiple Sclerosis Market Research and Analysis by Mode of Administration, 2025–2035 ($ Million)
33. Asia-Pacific Multiple Sclerosis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
34. Rest of the World Multiple Sclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
35. Rest of the World Multiple Sclerosis Market Research and Analysis by Types, 2025–2035 ($ Million)
36. Rest of the World Multiple Sclerosis Market Research and Analysis by Diagnostics Technologies, 2025–2035 ($ Million)
37. Rest of the World Multiple Sclerosis Market Research and Analysis by Mode of Administration, 2025–2035 ($ Million)
38. Rest of the World Multiple Sclerosis Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
1. Global Multiple Sclerosis Market Share by Types, 2025 Vs 2035 (%)
2. Global Primary Progressive MS Market Share by Region, 2025 Vs 2035 (%)
3. Global Progressive Relapsing MS Market Share by Region, 2025 Vs 2035 (%)
4. Global Relapsing Remitting MS Market Share by Region, 2025 Vs 2035 (%)
5. Global Secondary Progressive MS Market Share by Region, 2025 Vs 2035 (%)
6. Global Multiple Sclerosis Market Share by Diagnostics Technologies, 2025 Vs 2035 (%)
7. Global MRI For Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
8. Global Evoked Potential Test For Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
9. Global Spinal Fluid Test For Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
10. Global Others Multiple Sclerosis Diagnostics Technologies Market Share by Region, 2025 Vs 2035 (%)
11. Global Multiple Sclerosis Market Share by Mode of Administration, 2025 Vs 2035 (%)
12. Global Injectable Agents In Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
13. Global Oral Agents In Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
14. Global Intravenous Therapy In Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
15. Global Multiple Sclerosis Market Share by Drug Class, 2025 Vs 2035 (%)
16. Global Immunomodulators In Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
17. Global Immunosuppressant In Multiple Sclerosis Market Share by Region, 2025 Vs 2035 (%)
18. Global Multiple Sclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
19. US Multiple Sclerosis Market Size, 2025–2035 ($ Million)
20. Canada Multiple Sclerosis Market Size, 2025–2035 ($ Million)
21. UK Multiple Sclerosis Market Size, 2025–2035 ($ Million)
22. France Multiple Sclerosis Market Size, 2025–2035 ($ Million)
23. Germany Multiple Sclerosis Market Size, 2025–2035 ($ Million)
24. Italy Multiple Sclerosis Market Size, 2025–2035 ($ Million)
25. Spain Multiple Sclerosis Market Size, 2025–2035 ($ Million)
26. Russia Multiple Sclerosis Market Size, 2025–2035 ($ Million)
27. Rest of Europe Multiple Sclerosis Market Size, 2025–2035 ($ Million)
28. India Multiple Sclerosis Market Size, 2025–2035 ($ Million)
29. China Multiple Sclerosis Market Size, 2025–2035 ($ Million)
30. Japan Multiple Sclerosis Market Size, 2025–2035 ($ Million)
31. South Korea Multiple Sclerosis Market Size, 2025–2035 ($ Million)
32. Australia and New Zealand Multiple Sclerosis Market Size, 2025–2035 ($ Million)
33. ASEAN Economies Multiple Sclerosis Market Size, 2025–2035 ($ Million)
34. Rest of Asia-Pacific Multiple Sclerosis Market Size, 2025–2035 ($ Million)
35. Latin America Multiple Sclerosis Market Size, 2025–2035 ($ Million)
36. Middle East and Africa Multiple Sclerosis Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Multiple Sclerosis Market in 2025 is estimated to be around $31.0 billion.
North America holds the largest share in the Multiple Sclerosis Market.
Leading players in the Multiple Sclerosis Market include Biogen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA (EMD Serono Inc.), Novartis AG, Sanofi S.A., among others.
Multiple Sclerosis Market is expected to grow at a CAGR of 6.5% from 2026 to 2035.
Rising prevalence of multiple sclerosis, increasing awareness and early diagnosis, advances in disease-modifying therapies, and growing healthcare expenditure are driving the Multiple Sclerosis Market growth.
